Biomea's Phase 1 oral GLP-1 BMF-650 nears first weight-loss data
A placebo-controlled dose-escalation study will produce Biomea's first 28-day weight data for BMF-650, testing an oral GLP-1 agonist against a field led by injectable incumbents.
Executive Summary
- Biomea Fusion is approaching its first human weight-loss data for an oral GLP-1 agonist, a molecule designed to compete with a fast-maturing field of injectable and oral incumbents.
- The study's registered purpose is safety and tolerability across ascending doses, not a powered efficacy comparison, so the 28-day weight data will be directional rather than decision-grade.
- The trial has closed enrollment at its planned size and moved into its follow-up stage without any completion-date slippage, indicating the study is proceeding on schedule.
- The result lands in a field where later-stage oral and injectable GLP-1 programs are already generating clinical data, raising the bar for what an early Phase 1 signal needs to show to matter.
The catalyst
Biomea Fusion said it expects initial 28-day weight-reduction data from its Phase 1 GLP-131 study of BMF-650 in the third quarter of 2026, a window running from July 1 to September 30. The study, registered as NCT07223216, enrolls otherwise healthy overweight or obese adults and is designed as a single-ascending-dose and multiple-ascending-dose trial with a placebo comparator. The company had earlier guided to a second-quarter 2026 readout for the same data before the June disclosure moved the window to the third quarter. Biomea+1Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American ...Jun 5, 2026Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult ParticipantsNCT07223216
Probability of SuccessBased on the AppliedXL Probability of Success model. For more information about the methodology, read the research here.
What the trial can establish
The registered primary endpoint is safety and tolerability of BMF-650, repeated across five listed primary measures, with pharmacokinetics and food effect as secondary measures and weight change assessed only in the multiple-ascending-dose cohorts as an additional secondary endpoint. That design means the study is built to characterize dosing and tolerability first; the 28-day weight figure Biomea has flagged will be an early signal from a small cohort, not a powered comparison against an established efficacy bar. Biomea also disclosed in June that it added a cohort to test a rapid one-step titration schedule, moving from 200 mg once daily for one week to 400 mg once daily for three weeks, to explore whether faster up-titration improves the weight-reduction profile. NCT07223216+1Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult ParticipantsNCT07223216Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American ...Jun 5, 2026
Trial status
The trial moved from Recruiting to Active, not recruiting on April 9, 2026, with its target enrollment of 80 participants unchanged, a routine transition once enrollment completes ahead of follow-up. The primary completion date on file is May 1, 2026, and the study has logged one status change and no amendments to its primary completion date since its October 2025 start. The protocol has otherwise stayed stable, with no eligibility-criteria changes and no completion-date slippage recorded. NCT07223216Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult ParticipantsNCT07223216
The competitive field
BMF-650 enters an oral GLP-1 agonist field where Eli Lilly's orforglipron and Structure Therapeutics' aleniglipron are both already in Phase 3 testing for obesity, and Eli Lilly has a second oral candidate, LY4174794, in Phase 1. The broader obesity field is dominated by injectable incumbents, including Novo Nordisk's semaglutide and Eli Lilly's tirzepatide, both in Phase 4 testing, alongside next-generation injectables such as retatrutide and CagriSema in Phase 3. None of these programs shares BMF-650's specific molecular target in the data available, so the comparison here rests on modality and treatment stage rather than mechanism: BMF-650 is an early-stage oral small molecule entering a class where competitors are already generating late-stage human efficacy data. BiomeaBiomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American ...Jun 5, 2026
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.